![]() ![]() The yet-to-be peer-reviewed study found that overall effectiveness against severe COVID was 80 per cent with two doses of Covishield, and 69 per cent with two doses of Covaxin. Results from a recent study, which included researchers from the Indian Council of Medical Research, indicate that both Covishield, the other vaccine being used in India, and Covaxin significantly reduce the risk of severe COVID-19 and are effective against the Delta variant among Indians aged 45 years and above. The WHO added the vaccine to its list of approved emergency use COVID-19 vaccines earlier this month. In January this year, Covaxin was given emergency use approval (EUA) in India for people aged 18 and above. This study also shows that Covaxin meets the WHO's criteria for vaccines against the dreaded Delta variant, the company tweeted on Thursday. The results compared well with the 65.2 per cent efficacy against the Delta variant obtained during the controlled phase 3 clinical trials of Covaxin conducted among the general population. Bharat Biotech has said the study shows that Covaxin meets the World Health Organisation's criteria for vaccines against the Delta variant. Researchers noted that the Delta variant was the dominant strain in India during the study period, accounting for approximately 80 per cent of all confirmed COVID-19 cases.Ĭovaxin, developed by Hyderabad-based Bharat Biotech in collaboration with the National Institute of Virology-Indian Council of Medical Research (NIV-ICMR), Pune, is an inactivated whole virus vaccine administered in a two-dose regimen, 28 days apart. The post-vaccination observation period, she added, was very short. The original 77.8 per cent efficacy, she added, is based on short-term data collection to get emergency use approval (EUA). If there is a significant reduction in the severity of cases, 50 per cent is still a useful efficacy, it can decrease the load on poor healthcare infrastructure, Bal told PTI. Immunologist Bal noted that vaccine effectiveness is also about the extent of morbidity encountered during infectious disease. ![]() Although a vaccine that has high efficacy would be expected to be highly effective in the real world, it is unlikely to translate into the same effectiveness in practice. That said, this is not a bad level of protection at all it seems to me, Rath added.Ĭovishield, Covaxin, Z圜oV-D Makers to Assess Efficacy of Vaccine as They Await Data on OmicronĮfficacy is the degree to which a vaccine prevents disease, and possibly also transmission, under ideal and controlled conditions, while effectiveness refers to how well it performs in the real world. ![]() Typically, the latter is commonly less than the former, Rath, from the National Institute of Immunology (NII) in New Delhi, told PTI. We should note that the earlier one was a trial of 'efficacy', while this is a study of 'effectiveness'. Immunologist Satyajit Rath added that it is not clear whether the decrease in protection between the two studies is a real difference.Įven if it is, there are so many different possible contributory factors that it is difficult to offer even a semblance of likelihood. In general, all vaccines are at least marginally less effective against the Delta variant as compared to Wuhan strain, said Vineeta Bal from Pune's Indian Institute of Science Education and Research. The original 77 per cent figure is for Wuhan strain. One possible reason for this drop is also infection period when Delta variant was the most prominent. Earlier, an interim study based on Phase 3 clinical trials showed that two Covaxin doses had 77.8 per cent efficacy against symptomatic disease and present no serious safety concerns. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |